6Z4 Stock Overview
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Crinetics Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.60 |
| 52 Week High | US$46.40 |
| 52 Week Low | US$14.40 |
| Beta | 0.62 |
| 1 Month Change | 19.41% |
| 3 Month Change | 18.02% |
| 1 Year Change | 181.94% |
| 3 Year Change | 194.20% |
| 5 Year Change | 98.87% |
| Change since IPO | 102.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6Z4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.7% | -1.7% | -1.7% |
| 1Y | 181.9% | -15.7% | 1.4% |
Return vs Industry: 6Z4 exceeded the German Biotechs industry which returned -15% over the past year.
Return vs Market: 6Z4 exceeded the German Market which returned 1.1% over the past year.
Price Volatility
| 6Z4 volatility | |
|---|---|
| 6Z4 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6Z4 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6Z4's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 290 | R. Struthers | www.crinetics.com |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease.
Crinetics Pharmaceuticals, Inc. Fundamentals Summary
| 6Z4 fundamental statistics | |
|---|---|
| Market cap | €3.27b |
| Earnings (TTM) | -€201.89m |
| Revenue (TTM) | €3.78m |
848.2x
P/S Ratio-15.9x
P/E RatioIs 6Z4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6Z4 income statement (TTM) | |
|---|---|
| Revenue | US$4.01m |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.01m |
| Other Expenses | US$218.54m |
| Earnings | -US$214.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.75 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,345.85% |
| Debt/Equity Ratio | 0% |
How did 6Z4 perform over the long term?
See historical performance and comparison